Vaccine Partnering Terms and Agreements

Introduction

Abstract

The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in vaccine and adjuvant partnering deals
• Deal terms analysis
• Partnering agreement structure
• Partnering contract documents
• Top deals by value
• Most active dealmakers
• Average deal terms for vaccines

The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,500 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of vaccine deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of vaccine partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in vaccine partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of vaccine technologies and products.

Vaccine Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

Vaccine Partnering Terms and Agreements includes:

• Trends in vaccine dealmaking in the biopharma industry since 2007
• Analysis of vaccine deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life vaccine deals
• Access to over 1,500 vaccine deal documents
• The leading vaccine deals by value since 2007
• Most active vaccine dealmakers since 2007
• The leading vaccine partnering resources

In Vaccine Partnering Terms and Agreements, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Vaccine Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 vaccine deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise vaccine rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Vaccine Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of vaccine and adjuvant deal trends since 2007
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of vaccine agreements with numerous real life case studies
• Comprehensive access to over 1500 actual vaccine contracts entered into by the world's biopharma companies
• Detailed access to actual vaccine contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a vaccine agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in vaccine dealmaking

• 2.1. Introduction
• 2.2. Vaccine partnering over the years
• 2.3. Bigpharma vaccine dealmaking activity
• 2.4. Bigpharma not active in vaccine partnering
• 2.5. Vaccine partnering by deal type
• 2.6. Vaccine partnering by disease type

• 2.7. Average deal terms for vaccine partnering
  • 2.7.1. Vaccine partnering headline values
  • 2.7.2. Vaccine deal upfront payments
  • 2.7.3. Vaccine deal milestone payments
  • 2.7.4. Vaccine royalty rates

Chapter 3 - Leading vaccine deals

• 3.1. Introduction
• 3.2. Top vaccine deals by value
• 3.3. Top vaccine deals involving bigpharma

Chapter 4 - Bigpharma vaccine deals

• 4.1. Introduction
• 4.2. How to use bigpharma vaccine partnering deals

• 4.3. Bigpharma vaccine partnering company profiles
  • Abbott
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CSL
  • Daiichi Sankyo
  • Gilead Sciences
  • GlaxoSmithKline
  • Kyowa Hakko Kirin
  • Merck & Co
  • Merck KGaA
  • Mitsubishi Tanabe
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Takeda

Chapter 5 - Vaccine dealmaking directory

• 5.1. Introduction
• 5.2. Company A-Z

• 5.3. By stage of development
  • Discovery
  • Formulation
  • Marketed
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Regulatory

• 5.4. By deal type
  • Asset purchase
  • Co-development
  • Collaborative R&D
  • Contract service
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Research
  • Settlement
  • Spin out
  • Supply
  • Technology
  • Termination
  • Warranty

• 5.5. By therapy area
  • Immunology
  • Infectives
  • Inflammatory
  • Respiratory

• 5.6. By vaccine technology type

Chapter 6 - Vaccine partnering resource center

• 6.1. Online vaccine partnering
• 6.2. Vaccine partnering events

• 6.3. Further reading on vaccine dealmaking

• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Current Reports
• Recent titles from CurrentPartnering
• Order Form - Reports

• Appendix 1 - Vaccine dealmaking - by company A-Z
• Appendix 2 - Vaccine dealmaking - by deal type
• Appendix 3 - Vaccine dealmaking - by stage of development
• Appendix 4 - Vaccine dealmaking - by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Example vaccine partnering agreement

• Figure 1: Vaccine partnering since 2007
• Figure 2: Bigpharma - top 50 - vaccine deals 2007 to 2012
• Figure 3: Bigpharma vaccine deal frequency - 2007 to 2012
• Figure 4: Inactive bigpharma in vaccine partnering 2007-2012
• Figure 5: Vaccine partnering by deal type since 2007
• Figure 6: Vaccine partnering by disease type since 2007
• Figure 7: Vaccine partnering by infectives target since 2007
• Figure 8: Vaccine partnering by oncology target since 2007
• Figure 9: Vaccine deals with a headline value - by stage of development
• Figure 10: Vaccine deal headline value distribution, US$million - discovery stage
• Figure 11: Vaccine deal headline value distribution, US$million - preclinic stage
• Figure 12: Vaccine deal headline value distribution, US$million - phase I stage
• Figure 13: Vaccine deal headline value distribution, US$million - phase II stage
• Figure 14: Vaccine deal headline value distribution, US$million - phase III stage
• Figure 15: Vaccine deal headline value distribution, US$million - marketed stage
• Figure 16: Vaccine deal headline value - median value by stage of development
• Figure 17: Vaccine deals with upfront payment values - by stage of development
• Figure 18: Vaccine deal upfront payment distribution, US$million - discovery stage deals
• Figure 19: Vaccine deal upfront payment distribution, US$million - prelinic stage deals
• Figure 20: Vaccine deal upfront payment distribution, US$million - phase I stage deals
• Figure 21: Vaccine deal upfront payment distribution, US$million - phase II stage deals
• Figure 22: Vaccine deal upfront payment distribution, US$million - phase III stage deals
• Figure 23: Vaccine deal upfront payment distribution, US$million - marketed stage deals
• Figure 24: Vaccine deal upfront value - median value by stage of development
• Figure 25: Vaccine deals with milestone payment - by stage of development
• Figure 26: Vaccine deal milestone payment distribution, US$million - discovery stage deals
• Figure 27: Vaccine deal milestone payment distribution, US$million - prelinic stage deals
• Figure 28: Vaccine deal milestone payment distribution, US$million - phase I stage deals
• Figure 29: Vaccine deal milestone payment distribution, US$million - phase II stage deals
• Figure 30: Vaccine deal milestone payment distribution, US$million - phase III stage deals
• Figure 31: Vaccine deal milestone payment distribution, US$million - marketed stage deals
• Figure 33: Vaccine deals with royalty rates
• Figure 34: Top vaccine deals by value since 2007
• Figure 34: Top vaccine deals signed by bigpharma value since 2007
• Figure 35: Online partnering resources
• Figure 36: Forthcoming partnering events

Vaccine Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited in January 7, 2013. This report consists of 1258 Pages and the price starts from US $ 2795.

The contents of this page may be different from the latest version. Please contact us for details.